ASH 2023 | BelaRd trial: belamaf, lenalidomide, and dex in newly diagnosed MM
Meletios Dimopoulos, MD, Kapodistrian University of Athens School of Medicine, Athens, Greece, comments on the open-label Phase I/II BelaRd (NCT04808037) trial, which enrolled transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM). Patients were treated with a triplet regimen of belantamab mafodotin (belamaf), lenalidomide, and dexamethasone (dex). This combination therapy was well tolerated and showed promising clinical activity with minimal impact on vision-related functioning. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: Amgen, AbbVie, Takeda, Beigene, BMS, GSK, Janssen, Menarini, Regeneron, Sanofi
